{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T02:16:18Z","timestamp":1789352178462,"version":"build-2803163510"},"reference-count":11,"publisher":"Bioscientifica","issue":"6","license":[{"start":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T00:00:00Z","timestamp":1442275200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/deed.en_GB"}],"content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:p>\n                    Somatostatin analogues (SSA) have demonstrated antiproliferative activity in addition to efficacy for carcinoid symptom control in functional neuroendocrine tumors (NET). A\n                    <jats:italic>post hoc<\/jats:italic>\n                    analysis of the placebo arm of the RAD001 In Advanced Neuroendocrine Tumors-2 (RADIANT-2) study was conducted to assess the efficacy of octreotide long-acting repeatable (LAR) on progression-free survival (PFS) and overall survival (OS) estimated using the Kaplan\u2013Meier method. Out of 213 patients randomized to placebo plus octreotide LAR in RADIANT-2, 196 patients with foregut, midgut, or hindgut NET were considered for present analysis. Of these, 41 patients were SSA-treatment na\u00efve and 155 had received SSA therapy before study entry. For SSA-na\u00efve patients, median PFS by adjudicated central review was 13.6 (95% CI 8.2\u201322.7) months. For SSA-na\u00efve patients with midgut NET (\n                    <jats:italic>n<\/jats:italic>\n                    =24), median PFS was 22.2 (95% CI 8.3\u201329.5) months. For patients who had received SSA previously, the median PFS was 11.1 (95% CI 8.4\u201314.3) months. Among the SSA-pretreated patients who had midgut NET (\n                    <jats:italic>n<\/jats:italic>\n                    =119), the median PFS was 12.0 (95% CI 8.4\u201319.3) months. Median OS was 35.8 (95% CI 32.5\u201348.9) months for patients in the placebo plus octreotide LAR arm; 50.6 (36.4 \u2013 not reached) months for SSA-na\u00efve patients and 33.5 (95% CI 27.5\u201344.7) months for those who had received prior SSA. This\n                    <jats:italic>post hoc<\/jats:italic>\n                    analysis of the placebo arm of the large phase 3 RADIANT-2 study provides data on PFS and OS among patients with progressive NET treated with octreotide therapy.\n                  <\/jats:p>","DOI":"10.1530\/erc-15-0314","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T21:53:20Z","timestamp":1442354000000},"page":"933-940","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis"],"prefix":"10.1530","volume":"22","author":[{"given":"Jonathan R","family":"Strosberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Bajetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounir","family":"Aout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D","family":"Hainsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe B","family":"Ruszniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell","family":"\u00d6berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne E","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"2015110216263214000_22.6.933.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316158"},{"key":"2015110216263214000_22.6.933.2","doi-asserted-by":"crossref","unstructured":"Caplin ME Ruszniewski PB Pavel ME Cwikla JB Phan AT Raderer M Sedlackova E Cadiot G Wall LR Rindi G 2014b Progression-free survival (PFS) with lanreotide autogel\/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study. Journal of Clinical Oncology 32 (suppl 5s) abstract 4107.","DOI":"10.1200\/jco.2014.32.15_suppl.4107"},{"key":"2015110216263214000_22.6.933.3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.6.523"},{"key":"2015110216263214000_22.6.933.4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs353"},{"key":"2015110216263214000_22.6.933.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61742-X"},{"key":"2015110216263214000_22.6.933.6","doi-asserted-by":"publisher","DOI":"10.1159\/000335597"},{"key":"2015110216263214000_22.6.933.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8510"},{"key":"2015110216263214000_22.6.933.8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"2015110216263214000_22.6.933.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.04.005"},{"key":"2015110216263214000_22.6.933.10","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181ebaffd"},{"key":"2015110216263214000_22.6.933.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4377"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/22\/6\/933.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/22\/6\/933.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:53:16Z","timestamp":1784555596000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/erc\/article\/22\/6\/933-940\/33954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,15]]},"references-count":11,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.1530\/erc-15-0314","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,15]]}}}